Efficacy and safety of phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
- Author:
Zhou-Jun SHEN
1
;
Yan-Lan YU
Author Information
1. Department of Urology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China. shenzj@mail.hz.cn
- Publication Type:Journal Article
- MeSH:
Erectile Dysfunction;
drug therapy;
Humans;
Male;
Phosphodiesterase Inhibitors;
adverse effects;
therapeutic use;
Piperazines;
adverse effects;
therapeutic use;
Purines;
adverse effects;
therapeutic use;
Safety;
Sildenafil Citrate;
Sulfones;
adverse effects;
therapeutic use
- From:
National Journal of Andrology
2005;11(8):631-634
- CountryChina
- Language:Chinese
-
Abstract:
Phosphodiesterase 5 inhibitors are recommended as first-line treatment of erectile dysfunction in many guidelines, because of their convenience, higher efficacy, and less side-effects. Since its first launch in 1998, sildenafil has been currently the best investigated phosphodiesterase 5 inhibitor with respect to long-term trails and quantity. Clinical trials showed the efficacy of sildenafil compared with placebo in many of the groups of patients who have ED, including those with cardiovascular disease, diabetes mellitus, depression, radical prostatectomy and dialysis. Typically the adverse effects reported in patients from clinical trials of sildenafil have been mild to moderate, and commonly include flushing and dyspepsia and transient visual disturbances. This article summarized recent reports on efficacy and safety of phosphodiesters 5 inhibitors in the treatment of erectile dysfunction.
